Novartis drugs fail to help high-risk patients
ATLANTA (Reuters) - The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.
Regional News from the Arab World
economy -- sports -- politics
Nature and Development
Art and Culture
Health
Tourism
Classifieds
Jobs